好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Tau-PET in a Former American Football Player with Pathologically Confirmed Chronic Traumatic Encephalopathy
Aging, Dementia, and Behavioral Neurology
S15 - Behavioral and Cognitive Neurology (2:48 PM-3:00 PM)
010

Assess the regional relationship between in-vivo 18F-Flortaucipir (FTP) binding and postmortem tau pathology in a patient with pathologically-confirmed CTE.

Biomarkers for Chronic Traumatic Encephalopathy (CTE) are currently lacking. FTP detects tau pathology in Alzheimer’s disease, and positron emission tomography (PET) with FTP shows elevated binding in individuals at risk for CTE. No study, however, has assessed the correlation between in-vivo FTP PET and postmortem tau in CTE.

At a behavioral neurology tertiary referral center, a male former National Football League player with 17-years of American football exposure was clinically diagnosed with Traumatic Encephalopathy Syndrome. He underwent MRI, 18F-fluorodeoxyglucose, 11C-PIB and FTP PET 52 months prior to neuropathological examination. FTP Standardized Uptake Value Ratios (SUVR) (inferior cerebellar gray reference region) and W-score (age-adjusted Z-score) maps were qualitatively and quantitatively compared to phosphorylated tau (CP-13) immunostaining.

 

FTP uptake was distributed in a patchy, frontotemporal predominant pattern, overlapping with regions showing neurodegeneration on MRI and hypometabolism on 18F-fluorodeoxyglucose PET. 11C-PIB PET was negative. Pathological assessment revealed stage IV CTE, limbic argyrophilic grain disease, Stage 2 limbic-predominant age-related TDP-43 Encephalopathy, and Braak neurofibrillary tangle stage 3. Amyloid β and alpha synuclein immunostaining were negative. FTP W-maps matched areas of high post-mortem tau burden in left fusiform and inferior temporal gyri and juxta-cortical frontal white matter. High FTP W-scores with low tau were found in basal ganglia, thalamus, motor cortex and calcarine cortex. No regions with low FTP W-scores corresponded to areas with high pathological tau burden. A modest correlation, which did not reach statistical significance (rho=0.35, p=0.17), was found between FTP SUVR and tau area fraction at the regional level.  

FTP PET during life showed a modest correspondence with post-mortem pathology in CTE. Although based on a single case, FTP may have limited utility as a tau biomarker in CTE.

Authors/Disclosures
William G. Mantyh, MD (University of Minnesota)
PRESENTER
No disclosure on file
Salvatore Spina, MD (UCSF Memory and Aging Center) Dr. Spina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acsel Health. Dr. Spina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision Xtract. Dr. Spina has received research support from Tau Consortium. Dr. Spina has received research support from Chan Zuckerberg Initiative, LLC. Dr. Spina has received research support from Bluefield Project to Cure FTD.
No disclosure on file
No disclosure on file
David N. Soleimani-Meigooni, MD (University of California, San Francisco) Dr. Soleimani-Meigooni has nothing to disclose.
Elena Tsoy, MSc No disclosure on file
No disclosure on file
No disclosure on file
Lawren VandeVrede, MD, PhD (UCSF) The institution of Dr. VandeVrede has received research support from Alzheimer's Association.
No disclosure on file
No disclosure on file
No disclosure on file
Katherine L. Possin, PhD (U of CA San Francisco, Neurology) Dr. Possin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ClearView Healthcare Partners. The institution of Dr. Possin has received research support from Quest Diagnostics. The institution of Dr. Possin has received research support from NIH. The institution of Dr. Possin has received research support from The Global Brain Health Institute. The institution of Dr. Possin has received research support from The Rainwater Foundation.
Lea Grinberg Lea Grinberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curasen Inc. The institution of Lea Grinberg has received research support from NIH. The institution of Lea Grinberg has received research support from Eli Lilly. The institution of Lea Grinberg has received research support from BrightFouus. The institution of Lea Grinberg has received research support from Rainwater Charity Foundation.
Bruce L. Miller, MD, FAAN (University of California, San Francisco) Dr. Miller has nothing to disclose.
William W. Seeley, MD Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative.
Gil D. Rabinovici, MD, FAAN (UCSF Memory & Aging Center) Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.